Report
EUR 13.54 For Business Accounts Only

An unfavourable environment weighs on KISSEI PHARM.CO.LTD., which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of KISSEI PHARM.CO.LTD. (JP), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date June 28, 2019, the closing price was JPY 2,690.00 and its target price was estimated at JPY 2,260.31.
Underlying
Kissei Pharmaceutical Co. Ltd.

Kissei Pharmaceutical is a pharmaceutical company engaged in the research and development, manufacture and sale of pharmaceutical products. Co.'s major research and development areas are urogenital system, metabolism and endocrinology, as well as immunology and allergy. Co.'s principal products include a treatment for hyperphosphatemia "P-TOL Chewable," dysuria associated with benign prostatic hyperplasia (BPH) "Urief®," a rapid onset and short acting insulin secretagogue "Glufast®" and a therapeutic agent for patients with dry mouth "Salagenan®." In addition, Co., through its subsidiaries, is engaged in the purchase and sale of primary materials, and the development of information systems.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch